NIH awards AVM Biotechnology SBIR grant to study AVM0703 combined with standard of care in Non-Hodgkin's Lymphoma (NHL) to improve complete response rates without additional toxicities

August 25, 2022

Seattle – (BUSINESSWIRE) -**AVM Biotechnology** today announced the award of a **third Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI)**. This grant will evaluate the ability of the company's small molecule, AVM0703, in combination with the standard chemotherapy regimen, R-CHOP, to **reduce R-CHOP cycles** in an aggressive, immune-resistant murine B cell **Non-Hodgkin's Lymphoma** (NHL) model.

AVM0703 is currently the subject of an adaptive design expansion cohort clinical trial treating imminently terminal "no-option" NHL patients (NCT04329728). In the trial, which is nearing completion of the safety portion, **patients have experienced mild to moderate side-effects**. Although median survival has not been reached, patients have shown a **durable response to at least 11 months in multiple forms of NHL**. After a single, one-hour outpatient infusion, **AVM0703** induces and mobilizes **endogenous bispecific gamma delta** TCR+ invariant TCR+ **Natural Killer T-like cells**. It is **the only therapeutic known to mobilize these unique immune cells**.

While R-CHOP typically administered in six repeat cycles can elicit high response rates in NHL, relapse rates are high and long-term toxicities problematic. This includes secondary cancers caused by the treatment itself, as well as substantial neuro- and cardiac toxicities. An approach that increases complete response rates and lowers relapse rates without significant toxicities continues to be an unmet need for NHL. **AVM0703 in combination with** NHL standard of care such as **R-CHOP could reduce relapse rates** and even potentially **limit the total number of chemotherapy cycles** required for complete response, significantly impacting patient's short and long-term quality of life.

The company previously received two other SBIR Phase 1 grants from the NCI and National Institute of Diabetes and Digestive Kidney (NIDDK) as well as two Phase 2 grants from the same agencies. The previous NCI grants support the existing clinical trial as well as research utilizing AVM0703 as a preconditioning agent prior to chemotherapy. This brings AVM's total nondilutive government funding to $4.4 million validating the potential of AVM0703 in both cancer and Type 1 Diabetes.

AVM Biotechnology, a clinical stage company, is developing AVM0703 as a **treatment for NHL**, solid tumors, and autoimmune disorders. The research funded

by this grant will help to further elucidate the use of **AVM0703 in combination with chemotherapy** while the company is concurrently investigating AVM0703 as a monotherapy in relapsed/refractory "no-option" NHL. Previous preclinical research as well as patient outcomes in an FDA approved Compassionate Use Program indicate **AVM0703 has the potential to become an important treatment modality for NHL** patients solidifying AVM's influence in the immunotherapy space.

For information, contact Jena Dalpez, Director of Communications and Business Development, jdalpez@avmbiotech.com +1 206 906 9922 or visit avmbiotech.com.

Forward Looking Statement

This contains certain statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current facts and they may be accompanied by words such as "could," "would," "may," "potentially," "suggest," "believes," "expects," "should," and similar words or expressions. These forward-looking statements reflect our current views as of the date this is published, and are subject to risks, uncertainties, assumptions, changes in circumstances, and other factors; drug development and commercialization are highly risky and early clinical results in animals or humans may not reflect the full results from later stage or larger scale clinical trials. These forward-looking statements are subject to risks and uncertainties that could cause our actual results, performance, and expectations to differ materially from those expressed or implied by these statements, including statements about: future and ongoing drug development and timing; the applications of drugs to specific diseases; the potential for ongoing preclinical or clinical trial results; FDA or other regulatory findings and approvals; potential market opportunities; and the occurrence of future events or circumstances. There are risks and uncertainties involving and not limited to our ability to progress in our research and development efforts, complete clinical testing, achieve our expected results, commercialize our products, avoid infringement of patents, trademarks and other proprietary rights of third parties, protect products from competition, navigate the political environment, maintain sufficient capital and funding, avoid problems with our manufacturing processes, maintain our operations, and obtain regulatory approval to sell and market the drugs in the United States and elsewhere. The reader should not place any undue reliance on such forward-looking statements. We have no obligation to release publicly the results of any revisions to any of our forward-looking statements to reflect events or circumstances after the date these statements are made or to reflect the occurrence of unanticipated events, except as may be required by law.